Professional development Vacancies

Regarding amendments to the instructions for medical use of medicinal products containing sirolimus (sirolimus)

05.10.2021 1357 views

Taking into account the report of the Pharmacovigilance Risk Assessment Committee (PRAC) based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing sirolimus, the Committee for Medicinal Products for Human Use (CHMP) reached the following conclusions.

In view of the available data on interactions between medicinal products, including two cases registered in the registration certificate holder's global safety database, and in view of the results of pharmacokinetic studies, the PRAC concluded that an interaction between sirolimus and letermovir should be added to the section “Interaction with other medicinal products and other forms of interaction” of the instructions for medical use.

CHMP agrees with the scientific conclusions made by PRAC.

Based on the scientific conclusions, the CHMP considers that the benefit-risk balance of medicinal products containing sirolimus remains unchanged, provided that the appropriate changes are made to the instructions for medical use.

The CHMP recommends that registration certificate holders make the relevant changes to the instructions for medical use.

Перелік лікарських засобів, що містять сиролімус (sirolimus) і дозволені до медичного застосування в Україні (за даними Державного реєстру лікарських засобів станом на 28.09.2021).

To analyze the published information, the applicant must use the original text available at the linkhttps://www.ema.europa.eu/en/documents/scientific-conclusion/rapamune-h-c-psusa-00002710-202009-epar-scientific-conclusions-grounds-variation-terms-marketing_en.pdf